ABMC Announces Contract in the Dominican Republic

ABMC Distributor Signs Exclusive Contract with the National Network of Transportation

KINDERHOOK, N.Y.--(BUSINESS WIRE)--April 15, 2008--American Bio Medica Corporation (NASDAQ:ABMC) announced today that Vanter SA, ABMC's distributor in the Dominican Republic (DR), signed an exclusive contract with the National Network of Transportation to provide drug testing services for all dock personnel and all drivers delivering and receiving at the country's three major ports, Puerto Caucedo de Boca Chica, Puerto Haina and Puerto de Puerto Plata. The first 15,000 tests will be shipped in May, and it is expected that a minimum of approximately 40,000 tests will be required each year under this contract.

According to the International Narcotics Control Strategy Report released by the U.S. Department of State in March 2008, the Dominican Republic (DR) is a major transit country for cocaine and heroin from South America destined for U.S. and European markets. During 2007, the DR experienced an increase in air smuggling of cocaine while maritime deliveries via go-fast boats and cargo containers continued. The government of the DR cooperated in extraditing fugitives and deporting criminals to the U.S. Seizures of heroin, cocaine and MDMA were consistent with 2006, while drug related arrests increased by over 60 percent in 2007.

Vanter has made substantial inroads in the DR in many new markets. In the past few months alone they have signed contracts with customers in the mining and hotel industries, and in other free trade zones. Vanter says its objective is to grow its drug testing business by 80% in 2008. Nicanor Pena, President of Vanter stated, "We have made significant progress over the past 12 months with ABMC products in the Dominican Republic. This contract is just one of the many contracts we already have with various agencies in the country including the Army, Navy and Police."

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen(R), Rapid One(R), Rapid TEC(R), RDS(R) InCup(R), Rapid TOX(R) and Rapid TOX Cup(TM) products test for the presence or absence of drugs of abuse in urine, while OralStat(R) and Rapid STAT(TM) tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader(R) is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2007, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

CONTACT: American Bio Medica Corporation
Stan Cipkowski, Chief Executive Officer
800-227-1243, Ext 106
or
BPC Financial Marketing
John Baldissera, 800-368-1217

SOURCE: American Bio Medica Corporation